SanBio Company Limited
4592
Rank in Stocks
#13005
SanBio Company Limited is dedicated to the creation, production, and sale of... SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
Share Price
$5.42
Last synced: 2026-11-10
Market Cap
$422.93M
Change (1 day)
3.13%
Change (1 year)
-66.88%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade SanBio Company Limited (4592)
Category
Healthcare
Operating Margin for SanBio Company Limited (4592)
Operating Margin as of November 2026 TTM: 0.00%
According to SanBio Company Limited's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for SanBio Company Limited from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -1,227.29% | 143.62% |
| 2019 | -503.78% | -43.62% |
| 2018 | -893.47% | 338.88% |
| 2017 | -203.58% | 112.44% |
| 2016 | -95.83% | -237.65% |
| 2015 | 69.62% | -124.32% |
| 2014 | -286.27% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about SanBio Company Limited's operating margin
What was SanBio Company Limited's operating margin in 2025?
In 2025, SanBio Company Limited's operating margin was 0.00%, compared with 0.00% in 2024.
How has SanBio Company Limited's operating margin changed since 2020?
From 2020 to 2025, SanBio Company Limited's operating margin was highest in 2025 (0.00%) and lowest in 2020 (-1,227.29%).
How does SanBio Company Limited's operating margin compare with similar companies?
SanBio Company Limited's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.